rs532862288
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_020975.6(RET):c.3314C>T(p.Ala1105Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000291 in 1,613,990 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.3314C>T | p.Ala1105Val | missense_variant | Exon 20 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RET | ENST00000355710.8 | c.3314C>T | p.Ala1105Val | missense_variant | Exon 20 of 20 | 5 | NM_020975.6 | ENSP00000347942.3 | ||
RET | ENST00000615310.5 | c.*1484C>T | 3_prime_UTR_variant | Exon 17 of 17 | 5 | ENSP00000480088.2 | ||||
RET | ENST00000683007.1 | n.4277C>T | non_coding_transcript_exon_variant | Exon 16 of 16 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152120Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251494Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135920
GnomAD4 exome AF: 0.0000315 AC: 46AN: 1461870Hom.: 0 Cov.: 32 AF XY: 0.0000316 AC XY: 23AN XY: 727238
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152120Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74302
ClinVar
Submissions by phenotype
not specified Uncertain:2
Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: This variant is classidied as DM? in HGMD, related to urinary tract malformation. It is classified in ClinVar with 1 star as likely path by GeneDx, though their evidence provided does not support this classification. The Max MAF in ExAC is 0.02% (2/11578 Latino chrs). -
DNA sequence analysis of the RET gene demonstrated a sequence change, c.3314C>T, in exon 20 that results in an amino acid change, p.Ala1105Val. This sequence change has been described in the gnomAD database with a frequency of 0.006% in the Latino/admixed American subpopulation (dbSNP rs532862288). The p.Ala1105Val change affects a poorly conserved amino acid residue located in a domain of the RET protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Ala1105Val substitution. This sequence change does not appear to have been previously described in individuals with RET-related disorders. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Ala1105Val change remains unknown at this time. -
Multiple endocrine neoplasia type 2A Uncertain:2
- -
- -
Multiple endocrine neoplasia, type 2 Uncertain:2
This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1105 of the RET protein (p.Ala1105Val). This variant is present in population databases (rs532862288, gnomAD 0.006%). This missense change has been observed in individual(s) with congenital anomalies of the kidney or urinary tract and/or medullary thyroid cancer (PMID: 22729463, 33827484). ClinVar contains an entry for this variant (Variation ID: 201136). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change does not substantially affect RET function (PMID: 22729463). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This missense variant replaces alanine with valine at codon 1105 of the RET protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in two related individuals affected medullary thyroid carcinoma, these individuals also carried a pathogenic variant in the RET gene in trans that could explain the observed phenotype (PMID 33827484). This variant has been reported in an individual affected with renal dysplasia (PMID: 22729463). This variant has been identified in 6/251494 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Multiple endocrine neoplasia type 2A;C0025269:Multiple endocrine neoplasia type 2B;C0031511:Pheochromocytoma;C1833921:Familial medullary thyroid carcinoma;C3888239:Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at